EyePoint Pharmaceuticals

EYPT NASDAQ
1.440
-0.030
-2.04%
After Hours: 1.440 0 0.00% 16:36 08/20 EDT
Open
1.460
Prev Close
1.470
High
1.483
Low
1.410
Volume
175.03K
Avg Vol (3M)
409.31K
52 Week High
3.940
52 Week Low
1.190
% Turnover
0.16%
Market Cap
153.07M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers EyePoint Pharmaceuticals EYPT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
MORE >

Recently

Name
Price
%Change